Two US companies may launch COVID19 vaccines at the end of the year.
As the US epidemic continues and people are eager for the vaccine to arrive as soon as possible, two major US vaccine developers said that the time for the vaccine to be launched on the market, may be delayed until the end of this year, to next spring.
As of October 2, a report published by Johns Hopkins University in the United States, showed that there were 7.16 million confirmed infections in the United States and the epidemic caused more than 200,000 American deaths.
The news that President Trump and his wife and Hicks have been diagnosed with the virus, has increased the demand for vaccines in the US.
Albert Bourla, CEO of Pfizer Pharmaceuticals, said that his company will adhere to a scientific approach to trials of the COVID19 vaccines and will not shorten the development process due to political pressure.
Burla said he hopes that Pfizer may be able to produce 1 million doses of the COVID19 vaccines, before the end of this year.
It was previously reported that Pfizer will obtain clear data on the effectiveness of the vaccine, by the end of October and submit the vaccine approval document to the US Food and Drug Administration.
Stéphane Bancel, CEO of another major vaccine developer in the United States, Moderna Biotechnology, said recently that the company will not be able to launch COVID19 vaccines in the market this year and it will not be until next year at the earliest, quite likely spring.
Stéphane Bancel said at a medical conference on Wednesday, that Moderna will not be able to submit approval documents to the US Food and Drug Administration, until the end of January next year, for the public to use the company’s COVID19 vaccines.
Moderna said earlier this month that it may request the Food and Drug Administration to approve the COVID19 vaccines through an emergency approval process, as early as November 1.